Crispr Therapeutics AG (NASDAQ:CRSP) Insider Sells $1,000,400.00 in Stock

Crispr Therapeutics AG (NASDAQ:CRSP) insider Lawrence Otto Klein sold 20,000 shares of Crispr Therapeutics stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $50.02, for a total transaction of $1,000,400.00. Following the completion of the transaction, the insider now owns 31,579 shares in the company, valued at $1,579,581.58. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of NASDAQ CRSP traded down $0.07 during trading on Friday, hitting $49.11. 287,431 shares of the company were exchanged, compared to its average volume of 666,346. The stock has a market cap of $2.64 billion, a P/E ratio of -14.28 and a beta of 3.11. Crispr Therapeutics AG has a 1 year low of $22.22 and a 1 year high of $66.26. The stock has a fifty day moving average price of $42.99. The company has a debt-to-equity ratio of 0.08, a quick ratio of 15.84 and a current ratio of 15.84.

Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, April 29th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.03). The company had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $1.50 million. Crispr Therapeutics had a negative return on equity of 50.90% and a negative net margin of 8,839.02%. Crispr Therapeutics’s revenue for the quarter was down 78.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.62) earnings per share. As a group, sell-side analysts forecast that Crispr Therapeutics AG will post -3.82 earnings per share for the current year.

A number of research firms recently weighed in on CRSP. Evercore ISI began coverage on shares of Homology Medicines in a research report on Thursday, April 11th. They issued an “outperform” rating and a $29.00 price objective on the stock. Chardan Capital set a $73.00 price objective on shares of Crispr Therapeutics and gave the company a “buy” rating in a research report on Friday, June 7th. BidaskClub lowered shares of YRC Worldwide from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th. BTIG Research lifted their price objective on shares of Crispr Therapeutics from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, April 22nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price objective (down from $15.00) on shares of Nabriva Therapeutics in a research report on Wednesday, May 1st. Two analysts have rated the stock with a sell rating, five have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $49.88.

Several hedge funds and other institutional investors have recently modified their holdings of the business. Versant Venture Management LLC boosted its position in shares of Crispr Therapeutics by 17.7% during the 1st quarter. Versant Venture Management LLC now owns 4,248,888 shares of the company’s stock worth $151,770,000 after purchasing an additional 640,014 shares in the last quarter. ARK Investment Management LLC boosted its position in shares of Crispr Therapeutics by 52.7% during the 1st quarter. ARK Investment Management LLC now owns 2,023,017 shares of the company’s stock worth $72,262,000 after purchasing an additional 697,907 shares in the last quarter. Two Sigma Investments LP boosted its position in shares of Crispr Therapeutics by 25.2% during the 4th quarter. Two Sigma Investments LP now owns 509,572 shares of the company’s stock worth $14,558,000 after purchasing an additional 102,478 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of Crispr Therapeutics by 14.5% during the 4th quarter. Two Sigma Advisers LP now owns 473,100 shares of the company’s stock worth $13,516,000 after purchasing an additional 60,000 shares in the last quarter. Finally, Global Thematic Partners LLC boosted its position in shares of Crispr Therapeutics by 4.5% during the 1st quarter. Global Thematic Partners LLC now owns 468,525 shares of the company’s stock worth $16,735,000 after purchasing an additional 20,045 shares in the last quarter. Institutional investors own 48.96% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: Portfolio Manager

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.